Report : North America GMP Cell Therapy Consumables Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
At 27.0% CAGR, the North America GMP Cell Therapy Consumables Market is speculated to be worth US$ 26,093.86 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America GMP cell therapy consumables market was valued at US$ 6,233.00 million in 2022 and is expected to reach US$ 26,093.86 million by 2028, registering a CAGR of 27.0% from 2022 to 2028. Growing regulatory approvals for cell and gene therapy product and increase in strategic collaborations are the critical factors attributed to the North America GMP cell therapy consumables market expansion.
The companies in the GMP cell therapy consumables market is making strategic collaborations for the development of new products and cell therapy treatments. A few strategic collaborations in the GMP cell therapy consumables market are mentioned here. In October 2022, Pluristyx, panCELLa, and Implant Therapeutics management announced the corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technology and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients. Also, in June 2022, CellPoint and AboundBio entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities. The aim of this agreement is to expand the current market for CAR-T therapies and have an important impact on patients needing additional and improved treatment options. Further, in November 2021, Laurus Labs signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company, to acquire a 26.62% stake (fully diluted basis) for US$ 4.66, subject to the fulfillment of certain conditions. The increase in strategic collaborations among market players for the development of cell therapy has propelled the use of GMP cell therapy consumables to achieve the desired products, which drives the growth of the North America GMP cell therapy consumables market.
On the contrary, stringent regulatory policies hurdles the growth of North America GMP cell therapy consumables market.
Based on product, the North America GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held 52.9% share of North America GMP cell therapy consumables market in 2022, amassing US$ 3,294.17 million. It is projected to garner US$ 13,665.20 million by 2028 to expand at 26.8% CAGR during 2022–2028.
Based on cell therapy, the North America GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment held 59.6% share of North America GMP cell therapy consumables market in 2022, amassing US$ 3,715.93 million. It is projected to garner US$ 15,289.70 million by 2028 to expand at 26.6% CAGR during 2022–2028.
Based on process, the North America GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held 35.6% share of North America GMP cell therapy consumables market in 2022, amassing US$ 2,217.19 million. It is projected to garner US$ 9,501.69 million by 2028 to expand at 27.4% CAGR during 2022–2028.
Based on end use, the North America GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held 63.6% share of North America GMP cell therapy consumables market in 2022, amassing US$ 3,963.75 million. It is projected to garner US$ 16,860.54 million by 2028 to expand at 27.3% CAGR during 2022–2028.
Based on country, the North America GMP cell therapy consumables market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% share of North America GMP cell therapy consumables market in 2022. It was assessed at US$ 5,283.72 million in 2022 and is likely to hit US$ 21,947.55 million by 2028, exhibiting a CAGR of 26.8% during the forecast period.
Key players dominating the North America GMP cell therapy consumables market are Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc, among others.
- In June 2021, Sartorius, through its subgroup Sartorius Stedim Biotech acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company produces and markets cell culture components, such as growth factors, cytokines, and media in GMP quality for manufacturing cell and gene therapy products. Sartorius has acquired 51% of the company and at the beginning of 2023 and 2026, it plans to acquire the remaining shares of CellGenix.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com